Cocrystal Pharma Q2 FY26 net loss widens to $3.16 million; R&D expense climbs to $2.14 million

• Cocrystal Pharma posted a net loss of $3.16 million for the quarter ended June 30, 2026, widening from $2.06 million a year earlier.
• Research and development expense climbed to $2.14 million from $1.12 million, due to CDI-988 entering a norovirus Phase 1a clinical trial in 2026.
• General and administrative costs rose to $1.15 million from $986,000, on higher professional fees and insurance expense.
• Grant income was $105,000 versus no grant income a year earlier; interest income slipped to $10,000 from $28,000.
• Unrestricted cash totaled $2.17 million at June 30, 2026; a July 31 stock sale raised $5 million in gross proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037573), on August 13, 2026, and is solely responsible for the information contained therein.